PICASSO 3: Phase III Randomized Controlled Trial in Soft Tissue Sarcoma

ZIOPHARM Oncology, Inc. has initiated enrollment in its global Phase III randomized controlled trial of palifosfamide in combination with doxorubicin in subjects with front-line metastatic soft-tissue sarcoma. Progression-free survival (PFS) is the primary endpoint for accelerated approval, with overall survival (OS) as the primary endpoint for full approval. The secondary objectives are to assess the quality of life and safety and tolerability of the combination. >> Read More